黄金城集团

至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Inhibition of TPL2 by interferon-α suppresses bladder cancer through activation of PDE4D.

J Exp Clin Cancer Res. 2018; 
Qiang Z,, Zhou ZY,, Peng T,, Jiang PZ, Shi N,, Njoya EM,, Azimova B, Liu WL, Chen WH,, Zhang GL, Wang F.
Products/Services Used Details Operation
Catalog Peptides Human IFN-α-2a (Z03003) and human EGF (Z02691) were purchased from Genscript. Get A Quote

摘要

Drugs that inhibit the MEK/ERK pathway have therapeutic benefit in bladder cancer treatment but responses vary with patients, for reasons that are still not very clear. Interferon-α (IFN-α) is also used as a therapeutic agent for bladder cancer treatment but the response rate is low. It was found that IFN-α could enhance the cytotoxic effect of MEK inhibition. However, the potential mechanisms of that are still unclear. Understanding of the cross-talk between the IFN-α and MEK/ERK pathway will help enhance the efficacy of IFN-α or MEK inhibitors on bladder cancer.,Immunoprecipitation and pull-down assay were used to reveal the formation of signaling complex. The protein expressions were detected by western... More

关键词

COX-2; Interferon; PDE4D; TPL2; cAMP